CAY10585 prevented HIF-1 transcriptional activity with IC50 values of 2.6 and 0.7 µM, respectively.

CAY10415 is a potent, antidiabetic drug of the TZD structural class.

CASIN is a Cdc42 GTPase inhibitor (IC50 = 2 μM).

Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent.

Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2).

Cardamonin, isolated from the fruits of Alpinia species, is a chalconoid with anti-inflammatory and anti-tumor activity.

Carboplatin is a chemotherapy drug by binding to DNA and interfering with the cell's repair mechanism.

Capromorelin tartrate is a potent ghrelin receptor agonist/growth hormone secretagogue (Ki = 7 nM).

Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggrega

Cangrelor (AR-C69931MX) is a potent, selective P2T/P2Y12 receptor antagonist with IC50 of 0.4 nM against ADP-induced aggregation of human platelets.

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.

Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.

Cambendazol is an antihelmintic that, at a dose of 50 mg/kg/day in mice, eradicates S. ratti adult worms from intestine and S. stercoralis larva from muscle.

Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.

CAL-101 is a selective p110δ inhibitor with IC50 of 2.5 nM; shown to have 40- to 300-fold greater selectivity for p110δ thanp110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.

Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.

CA4948-Analog is an analog of Emavusertib. It has similar property to CA-4948, which is a potent, and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. It was reported in patent WO 2015104688. Emavusertib, also known as CA-4948 i

CA-074 Me is a selective and cell-permeable inhibitor of cathepsin B.

C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors.

BYL719 is a potent and selective PI3Kα inhibitor with IC50 of 5 nM, ;liitle or no effect on PI3Kβ/γ/δ.

BX-912 is a selective inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1) with IC50 of 12 nM; >10 fold selectivity over PKA, PKC, C-Kit, EGFR etc.

BX795 is a potent and selective dual inhibitor of TBK1/PDK1 with IC50s of 2 nM/6 nM respectively; > 50 fold selectivity over PKA, PKC, c-Kit, GSK3β etc.

BX517 is a novel phosphoinositide-dependent kinase-1 (PDK1) inhibitor.

BX471 is a potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1); exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

BVT-948 (SPS8I-3) is a noncompetitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) with IC50 of 0.09-1.7 uM. Results show that the effect of BVT948 (BVT.948) is to strengthen the insulin signal and has no effects on the duration of th

BVT 2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor,protecting osteoblasts against endogenous glucocorticoid induced dysfunction.

Bumetanide